<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01037881</url>
  </required_header>
  <id_info>
    <org_study_id>LEO 29102-C21</org_study_id>
    <secondary_id>EudraCT Number 2009-013792-22</secondary_id>
    <nct_id>NCT01037881</nct_id>
  </id_info>
  <brief_title>LEO 29102 Cream in the Treatment of Atopic Dermatitis</brief_title>
  <official_title>A Phase 2, Proof of Concept and Dose Finding Study, Investigating Treatment Efficacy of LEO 29102 Cream, LEO 29102 Cream Vehicle, and Elidel® Cream 10 mg/g, After Cutaneous Administration Twice Daily for 4 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LEO Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LEO Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a proof of concept and dose finding Phase II trial comparing 5 dose strengths with
      vehicle and an active comparator (Elidel cream 10 mg/g) in a 4 week, twice daily treatment
      regimen in mild to moderate atopic dermatitis patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in eczema area and severity index (EASI) score from baseline to end of treatment</measure>
    <time_frame>4 weeks treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in EASI</measure>
    <time_frame>4 weeks treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IGA</measure>
    <time_frame>4 weeks treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">183</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>LEO 29102 0.03 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 0.1 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 0.3 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 1.0 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 2.5 mg/g cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LEO 29102 cream vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Elidel® cream (pimecrolimus) 10 mg/g</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEO 29102</intervention_name>
    <description>comparison of different dosages of drug</description>
    <arm_group_label>LEO 29102 0.03 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 0.1 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 0.3 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 1.0 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 2.5 mg/g cream</arm_group_label>
    <arm_group_label>LEO 29102 cream vehicle</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elidel®</intervention_name>
    <description>comparison</description>
    <arm_group_label>Elidel® cream (pimecrolimus) 10 mg/g</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of atopic dermatitis defined according to Hanifin and Rajka

          -  IGA assessment scored as mild (2) to moderate (3) atopic dermatitis

          -  Treatment lesions located on the trunk and limbs

          -  Treatment lesions involving 3% to 10% of the total body surface area

          -  Patients of either gender between 18 years and 65 years of age

        Exclusion Criteria:

          -  Systemic treatment with immunosuppressive drugs or corticosteroids within 6 weeks
             prior to randomisation

          -  Topical treatment with immunomodulators (pimecrolimus, tacrolimus) within 2 weeks
             prior to randomisation

          -  Topical treatment with corticosteroids from WHO groups II, III or IV within 1 week
             prior to randomisation

          -  Use of topical or systemic antibiotics within 2 weeks prior to randomisation

          -  PUVA or UVB therapy within 4 weeks prior to randomisation

          -  Clinical infection (viral, fungal or bacterial) on the treatment area

          -  Known or suspected severe renal insufficiency or severe hepatic disorders

          -  Patients with history of an immunocompromised disease (e.g., lymphoma, HIV,
             Wiskott-Aldrich Syndrome)

          -  Patients with concomitant serious disease (e.g., cancer) which might affect the AD
             treatment in this trial

          -  Females who are pregnant or are breast feeding

          -  Females intending to temporarily or permanently stop their hormonal contraceptive
             regime during and up to one month post study termination visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sakari Reitamo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windsor Clinical Research Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <zip>00250</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik und Poliklinik für Dermatologie, Universität Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Finland</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2009</study_first_submitted>
  <study_first_submitted_qc>December 22, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2009</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pimecrolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

